Want to see AU:AHE full AI Analyst Report?
Top Page
MedAdvisor Limited
(Sydney:AHE)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.01
Action:Reiterated
Date:10/24/26
The score is primarily held down by weak financial performance—persistent losses, negative equity in recent years, and ongoing cash burn—indicating elevated fundamental risk. Technical indicators provide only limited support (some short-term momentum but a still-weak longer-term trend). Valuation does not offset the risk because profitability is negative (negative P/E) and no dividend yield is available.
Positive Factors
Integrated healthcare technology platform
The company serves multiple participants in the medication ecosystem through one healthcare technology platform. Its pharmacy workflow, medication-management, and consumer engagement tools provide a broad operating base that can support recurring relationships and diversified healthcare program opportunities over time.
Negative Factors
Negative shareholder equity
Negative shareholder equity materially weakens the balance sheet and limits financial flexibility. It also increases perceived solvency risk because the recorded asset base does not provide a positive equity buffer against continued losses, making recovery more dependent on improved operations or additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated healthcare technology platform
The company serves multiple participants in the medication ecosystem through one healthcare technology platform. Its pharmacy workflow, medication-management, and consumer engagement tools provide a broad operating base that can support recurring relationships and diversified healthcare program opportunities over time.
Read all positive factors
MedAdvisor Limited (AHE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.29M
Dividend YieldN/A
Average Volume (3M)310.45K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth-46.09%
EPS Growth70.70%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding637,981,000
10 Day Avg. Volume314,767
30 Day Avg. Volume310,450
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-3.12
Price to Sales (P/S)0.22
P/FCF Ratio-0.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
MedAdvisor Limited Business Overview & Revenue Model
Company Description
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-drive...
How the Company Makes Money
null...
MedAdvisor Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 33.96M | 62.99M | 122.11M | 97.96M | 67.75M |
| Gross Profit | -3.49M | 3.97M | 23.63M | 12.59M | -1.84M |
| EBITDA | -16.53M | -9.87M | 7.05M | -3.03M | -11.29M |
| Net Income | -19.97M | -60.21M | 792.13K | -11.31M | -17.35M |
Balance Sheet | |||||
| Total Assets | 16.59M | 39.84M | 98.78M | 95.91M | 78.44M |
| Cash, Cash Equivalents and Short-Term Investments | 9.53M | 10.30M | 15.58M | 14.20M | 7.58M |
| Total Debt | 131.74K | 17.40M | 12.61M | 13.09M | 13.41M |
| Total Liabilities | 19.03M | 41.46M | 47.20M | 47.45M | 43.89M |
| Stockholders Equity | -2.44M | -1.62M | 51.58M | 48.46M | 34.55M |
Cash Flow | |||||
| Free Cash Flow | -10.27M | -14.37M | 3.35M | -1.63M | -548.13K |
| Operating Cash Flow | -10.27M | -14.37M | 5.19M | -1.45M | -236.32K |
| Investing Cash Flow | 9.92M | -2.18M | -2.80M | -3.23M | -290.79K |
| Financing Cash Flow | 284.23K | 11.34M | -831.97K | 12.42M | 1.86M |
MedAdvisor Limited Technical Analysis
Negative
―
Price Trends
0.01
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
44.76
Neutral
-122.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHE, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 0.01, equal to the 50-day MA of 0.01, and equal to the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of -122.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AHE.
MedAdvisor Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$155.23M | 67.65 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$14.31M | -5.88 | -416.53% | ― | 113.42% | 29.17% | |
48 Neutral | AU$117.49M | -6.43 | -203.69% | ― | -1.53% | 28.29% | |
45 Neutral | AU$50.15M | -17.58 | -9.39% | 6.52% | 4.06% | -625.00% | |
44 Neutral | AU$8.29M | -0.42 | -614.15% | ― | -46.09% | 70.70% | |
40 Underperform | AU$15.48M | -1.71 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
AU:AHE
MedAdvisor Limited
0.01
-0.02
-55.17%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.14
-0.05
-26.32%
AU:PHX
PharmX Technologies
0.08
-0.07
-46.43%
AU:ALC
Alcidion Group Limited
0.12
0.03
27.78%
AU:ICR
InteliCare Holdings Limited
0.02
>-0.01
-4.76%
AU:PCK
PainChek Ltd
0.07
-0.39
-83.91%
MedAdvisor Limited Corporate Events
Adheris Health posts Q1 margin uplift as it pivots to higher-growth digital pharma programs
Oct 27, 2026
Adheris Health reported modest year-on-year revenue and gross profit growth for Q1 FY27, with a sharp rebound versus the prior quarter driven by out-of-cycle bookings, customer win-backs and program add-ons. Gross margin improved to 45.2% on lower...
Adheris Health Dispatches AGM Documents and Promotes Digital Investor Communication
Oct 19, 2026
Adheris Health Limited has dispatched key documents for its upcoming Annual General Meeting to shareholders, including the formal meeting notice, notice of access and proxy forms, ahead of the 18 November 2026 session in Melbourne. The company is ...
Adheris Health aligns reporting calendar and shifts to U.S. dollar reporting
Oct 6, 2026
Adheris Health Limited has shifted its financial year-end from 30 June to 31 December to align its reporting cycle with key U.S.-based pharmaceutical clients and their health program planning timelines. The company will operate a six‑month t...
EBOS Exits Substantial Holding in MedAdvisor’s Adheris Health Unit
Oct 2, 2026
MedAdvisor’s subsidiary Adheris Health Limited is positioned in the health technology and pharmaceutical services industry, delivering digital adherence and patient engagement solutions to pharmacies, healthcare professionals and drug manufa...
Adheris Health Director Kate Hill Increases Direct Shareholding via Off-Market Trade
Oct 1, 2026
Adheris Health Limited has disclosed a change in the holdings of director Catherine (Kate) Jane Hill, who increased her direct ownership in the company through an off-market trade at a nominal price of $0.01 per share. Following the transaction, H...
Adheris Health Leaders Boost Stakes as Insider Buying Signals Confidence
Oct 1, 2026
Adheris Health has disclosed that its board and management have acquired about 27 million shares, equivalent to 4.2% of the company’s outstanding stock, while a long-term supportive shareholder has purchased an additional 27 million shares r...
Adheris Health Issues FY26 Results Presentation with Extensive Legal Disclaimers
Sep 1, 2026
Adheris Health released its FY26 results presentation, framing the document as general information rather than investment advice and emphasizing that it does not account for individual investor circumstances. The company stresses that the material...
Adheris Health appoints new CFO to support U.S. rebuild and profitability push
Aug 31, 2026
Adheris Health Limited has appointed Alison Hale as Chief Financial Officer, effective 1 September 2026, replacing outgoing CFO Sean Slattery. Hale brings experience from Deloitte and senior finance roles at the Linde Group and Elgas Limited, with...
Adheris Health Cuts Costs and Stabilises Cash Flow as Revenue Slides
Aug 31, 2026
Adheris Health reported FY26 revenue of A$34.0 million from continuing operations, down 46% year on year, with gross profit and margins also weaker amid lower customer renewals and reduced bookings in the prior pharma budget cycle. Statutory net l...
Adheris Health Completes Strategic Reset to Refocus on U.S. Growth
Aug 31, 2026
Adheris Health has completed a strategic reset over the year to 30 June 2026, upgrading its technology platform to deliver programs at scale and refreshing its executive leadership while recommitting to core customer relationships. The company has...
Adheris Health lodges ASX governance key and updates corporate oversight framework
Aug 30, 2026
Adheris Health Limited has lodged its Appendix 4G and related corporate governance disclosures for the year ended 30 June 2026 with the ASX. The company has elected to host its corporate governance statement on its website, confirming board approv...
Adheris Health Sets Date for FY26 Results and Investor Webinar
Aug 28, 2026
Adheris Health Limited, a healthcare technology company specializing in data-driven patient engagement and medication adherence solutions for pharmaceutical manufacturers, pharmacies, and healthcare providers, operates the THRiV platform to person...
Adheris Health Faces US Legal Action Over Terminated IT Services Deal
Jul 31, 2026
Adheris Health Limited has disclosed that its U.S. subsidiary, Adheris LLC, has been named as a defendant in legal proceedings brought by Mindsprint Pte. Ltd. in the United States District Court for the Southern District of New York. The dispute a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.